The cost-effectiveness of using pneumococcal conjugate vaccine (PCV13) versus pneumococcal polysaccharide vaccine (PPSV23), in South African adults

Posted on by

PLoS One
http://www.plosone.org/
(Accessed 1 Feb 2020)

 

The cost-effectiveness of using pneumococcal conjugate vaccine (PCV13) versus pneumococcal polysaccharide vaccine (PPSV23), in South African adults
Charles Feldman, Sipho K. Dlamini, Shabir A. Madhi, Susan Meiring, Anne von Gottberg, Janetta C. de Beer, Margreet de Necker, Marthinus P. Stander
Research Article | published 29 Jan 2020 PLOS ONE
https://doi.org/10.1371/journal.pone.0227945